期刊
JOURNAL OF VETERINARY INTERNAL MEDICINE
卷 29, 期 6, 页码 1569-1577出版社
WILEY
DOI: 10.1111/jvim.13633
关键词
Amyloid-beta; Canine; Dementia; Geriatric; Longitudinal
BackgroundCanine cognitive dysfunction (CCD) is an age-dependent neurodegenerative condition dominated by changes in behavioral patterns. Cohort studies investigating cognitive status in dogs are lacking. ObjectivesTo investigate cognitive function, progression of age-related behavioral changes, survival, and possible biomarkers of CCD in aged dogs. AnimalsFifty-one dogs >8 years old; 21 with no cognitive deficits, 17 with mild cognitive impairments (MCI) and 13 with CCD. MethodsLongitudinal study. Recruitment period of 12 months and an observational period of 24 months including a baseline and 3 planned subsequent assessments. Cognitive status was determined using validated questionnaires. Plasma A-peptides were quantified using commercial ELISA assays and cytokines by a validated immunoassay. ResultsSigns characterizing dogs with CCD were aimless wandering, staring into space, avoid getting patted, difficulty finding dropped food and anxiety. Thirty-three percent of dogs with a normal cognitive status progressed to MCI and 22% classified as MCI progressed to CCD during the study period. For 6 dogs diagnosed with CCD, signs of cognitive dysfunction increased with time. A diagnosis of CCD did not affect survival. The level of plasma A(42) was significantly increased (P < .05) in the CCD group (92.8 24.0 pg/mL) compared to the MCI (77.0 +/- 12.3 pg/mL) and normal group (74.9 +/- 10.0 pg/mL), but no significant differences in concentrations of systemic inflammatory markers were detected. ConclusionsCanine cognitive dysfunction is a progressive disorder with an individual variability in the rate of cognitive decline and clinical signs. Plasma A(42) seems to be an interesting plasma biomarker of CCD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据